أستونيا - الإستونية - Ravimiamet

pharmaceutical works polpharma s.a. - olansapiin - suus dispergeeruv tablett - 15mg 56tk; 15mg 28tk; 15mg 30tk

أستونيا - الإستونية - Ravimiamet

pharmaceutical works polpharma s.a. - olansapiin - suus dispergeeruv tablett - 20mg 30tk; 20mg 56tk; 20mg 28tk

أستونيا - الإستونية - Ravimiamet

pharmaceutical works polpharma s.a. - kvinapriil - õhukese polümeerikattega tablett - 20mg 30tk

أستونيا - الإستونية - Ravimiamet

pharmaceutical works polpharma s.a. - kvinapriil - õhukese polümeerikattega tablett - 40mg 30tk

أستونيا - الإستونية - Ravimiamet

pharmaceutical works polpharma s.a. - kvinapriil - õhukese polümeerikattega tablett - 10mg 30tk

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

1 a pharma gmbh - rivastigmiin - alzheimer disease; dementia; parkinson disease - psychoanaleptics, - kerge kuni mõõdukalt raskekujulise alzheimeri tõve sümptomaatiline ravi. sümptomaatiline ravi kerge kuni mõõdukalt raske dementsuse patsientidel, kellel on idiopaatiline parkinsoni tõbi.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

teva pharma b.v. - pioglitasoonvesinikkloriid - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. pärast algatamist ravi pioglitazone, patsiente tuleks läbi vaadata pärast 3 kuni 6 kuud hinnata piisavust ravi (e. vähendada hba1c). patsientidel, kes ei näita piisava vastuse, pioglitazone tuleks lõpetada. arvestades võimalikke riske pikaajalise ravi, arstid tuleks kinnitada järgmiste korraliste kommentaare, mis kasu pioglitazone on hooldatud.

أستونيا - الإستونية - Ravimiamet

pharmaceutical works polpharma s.a. - kandesartaan - tablett - 8mg 28tk; 8mg 14tk; 8mg 56tk

أستونيا - الإستونية - Ravimiamet

pharmaceutical works polpharma s.a. - kandesartaan - tablett - 4mg 14tk; 4mg 28tk

أستونيا - الإستونية - Ravimiamet

pharmaceutical works polpharma s.a. - kandesartaan - tablett - 32mg 56tk; 32mg 14tk